Psoriasis

Tildrakizumab continued to demonstrate efficacy after 5 years of treatment for psoriasis, according to pooled data from the reSURFACE 1 and reSURFACE 2 trials.

Systemic inflammation burden and disease activity are independent risk factors for heart failure among patients with psoriatic disease, according to data published in Arthritis Care & Research.

Men with poor cardiorespiratory fitness levels during late adolescence were more likely to develop psoriasis or psoriatic arthritis later in life, according to a study.

Patients with skin of color have unique challenges when it comes to treating psoriasis.

Welcome to this special edition of Healio Psoriatic Disease, which focusses on the management of psoriasis in patients with skin of color, coinciding with Black History Month.

Identifying and treating psoriasis in skin of color present a unique set of challenges for practitioners, leading to a call for advanced education.

Despite the obstacles caused by insurance companies and the pandemic, patients can still be safely managed with biologics. Bimekizumab, a treatment in the pipeline, could reduce burden and improve outcomes in psoriasis, a speaker said.

Patients with nail psoriasis alongside psoriatic arthritis demonstrate worse disease activity, quality of life and work productivity than those without nail involvement, according to data published in The Journal of Rheumatology.

While novel drugs are changing the game in psoriatic arthritis, early diagnosis and interdisciplinary management remain keys to successful outcomes, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.

Deucravacitinib improved psoriasis compared with placebo and apremilast in a phase 3 study, Bristol Myers Squibb announced in a press release.